Panbela Therapeutics Inc. PBLA
0.01
0.00
0.00%
as of 24 Sep
- Market cap
- $3.4M
- P/E
- 0.0×
Follow PBLA
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
| 270.37% | 991.19% | 8,377.88% | 396.00% |
+8 more TTM periods Free account |
|
| (353.47%) | (197.31%) | (201.99%) | (301.11%) | ||
ROIC |
0.00% | 0.00% | (2,305.04%) | 0.00% | |
Return on Tangible Assets |
186.44% | 178.42% | 312.23% | 272.88% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.97) | (3.90) | (7.96) | (227.98) | |
Free Cash Flow |
(14.40) | (18.95) | (24.89) | (24.85) | |
Capital Expenditures |
1.18 | 1.18 | — | 0.40 | |
Piotroski F-Score |
2.00 | 1.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
112.59% | 318.76% | (1,959.84%) | (824.59%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.01) | (0.01) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.56 | 0.70 | 0.91 | 1.00 | |
Capex/Depreciation |
0.00 | 0.00 | — | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.21) | (4.15) | (7.96) | (231.64) | |
Capex per Share |
0.24 | 0.24 | 0.00 | 3.66 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates